TACE With Thermosensitive Nanogel Versus Embosphere for HCC

Inclusion Criteria: 1. Chinese Liver Cancer Staging Scheme, stage IIb-Illa, as well as those with stage Ia-Ila HCC, unsuitable or unwilling to undergo surgical resection, transplantation, or ablation; 2. Liver function status: Child-Pugh A or B 3. Eastern Cooperative Oncology Group score: 0-2 points; 4. With at least one measurable, unembolized liver tumor lesion (1-10 cm) ; 5. Willing to participate in this trial and sign the informed consent. Exclusion Criteria: 1. The target lesion has been embolized before or require combined with other treatment(s); 2. Diffuse or with extrahepatic metastasis; 3. Coagulation dysfunction (PT prolonged beyond the upper limit of normal for 3 seconds); 4. Severe renal dysfunctions (creatinine clearance rate \<30 ml/min); 5. Severe liver dysfunctions (alanine aminotransferase or aspartate aminotransferase exceeding the upper limit of normal by 5 times); 6. Main portal vein was completely occluded and no collateral blood supply was established; 7. With uncorrectable arteriovenous fistula or portal vein fistula; 8. Severe cachexia or hepatic encephalopathy; 9. With active infection; 10. Significant reductions in white blood cells or platelets (white blood cells\<3.0x109/L, platelets\<50x109/L) that cannot be corrected; 11. Pregnant or lactating women; 12. Difficulty in selective catheterization; 13. With the severe risk of non-target embolization; 14. Severely allergic to contrast agents or the embolic materials; 15. Participating in ongoing trial; 16. Unsuitable judged by the investigator.